WTX 221
Alternative Names: WTX-221Latest Information Update: 10 Apr 2023
At a glance
- Originator Westlake Therapeutics
- Class Antigouts; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gout
Most Recent Events
- 10 Apr 2023 Westlake Therapeutics plans a phase 0 (Early phase I) trial for Gout in China (IV, Infusion) (NCT05800041)
- 21 Jul 2022 Westlake Therapeutics has patent protection for the development of red blood cell therapy technology (Westlake Therapeutics website; July 2022)
- 21 Jul 2022 Preclinical trials in Gout in China (Parenteral) (Westlake therapeutics pipeline, July 2022)